31 results about "Hemopexin" patented technology

Fusion proteins comprising a first protein fused to hemopexin are provided, said fusion proteins exhibit an increased circulation time.

The present invention is directed to methods of producing recombinant functional heme-binding proteins with complete heme incorporation and purified preparations of the same. The present invention is further directed to methods of identifying agents that modulate the activity of heme-binding proteins.

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analysed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta / delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact / cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase / arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO / 2008 / 031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.

The invention relates to the biological field, in particular to a serum-free medium for stem cells. A medium additive comprises 5-30 g / L of human serum albumin, 1-10 g / L of plant-derived recombinant human serum transferring, 0.1-8 g / L of alpha1 acid glycoprotein, 0.1-8 g / L of alpha2-HS-glycoprotein, 0.05-5 g / L of apolipoprotein AI, 0.05-5 g / L of apolipoprotein AII, 0.01-2 g / L of hemopexin, 0.05-5 g / L of adenosine deaminase, 0.03-3 g / L of serine protease inhibitors, 0.01-3 g / L of transthyretin and 0.01-3 g / L of human insulin. According to the serum-free medium for stem cells, pathogen pollution from animal origins is eliminated, the components are defined, and therefore reproducibility and controllability of the serum-free medium are better than those of a serum medium; the effect of in-vitro culture of stem cells is superior to the effect of the serum medium, the expansion speed of stem cells is increased, and culture time for stem cells is greatly shortened.

The present invention provides compounds for disrupting the binding of a matrix metalloprotease (MMP) protein to a substrate protein at an interaction site other than the protease catalytic site. In particular the inventive compounds inhibit the MMP's ability to cleave a substrate protein. In some cases the compound may prevent activation of transforming growth factor beta (TGFβ). The compounds are preferably polypeptide fragments of the hemopexin-like domain of the MMP, but may be mimetics thereof or peptides or mimetics of the portion of the MMP substrate protein to which the MMP interacts.

Provided herein are methods for the diagnosis of obstructive airways diseases such as asthma and chronic obstructive pulmonary disease, and the discrimination between such diseases based on the expression profiles of biomarker proteins and combinations of biomarker proteins. In particular embodiments the biomarker proteins are selected from ceruloplasmin, haptoglobin, hemopexin, -2-macroglobulin, prothrombin, immunoglobulin A and complement factor H.

This invention provides novel assays for the detection of dysfunctional HDL. The assays are good diagnostics and / or prognostics for atherosclerosis or other pathologies characterized by an inflammatory response. In certain embodiments the methods involve measurements of heme-related HDL-associated proteins (e.g., haptoglobin, hemopexin, etc.), and / or measurements of the relative distribution of HDL-associated proteins between HDL and the non-lipoprotein fractions of plasma / serum, and / or measurements of the ability of pro-inflammatory HDL to consume nitric oxide, and / or measurement of the ability of HDL to inhibit LDL aggregation.

The present invention relates generally to a method of purifying proteins. More specifically, the present inventions relates to a method of purifying haptoglobin and hemopexin from the same starting material, and uses thereof.

The invention belongs to the field of genetic engineering, and discloses a gene TaHBP1 with a heme-binding domain, and a recombinant interference vector and an application thereof. The gene TaHBP1 with the heme-binding domain has the cDNA sequence of SEQ ID NO.1 and a coding amino acid sequence of SEQ ID NO.2. The gene comes from ordinary triticum asetivum l. Yangmai 158. The expression of the TaHBP1 in powdery mildew-susceptible triticum asetivum l. variety Yangmai 158 is induced to enhance by erysiphe cucurbitacearum, and the expression level is much higher than the expression level in disease-resistant triticum asetivum l. variety Nannong 9918. A positive sequence of the TaHBP1 is inserted between BamHI and KpnI digestion sites of pWMB006, and at the same time, a reverse sequence is inserted between SpeI and ScI of pWMB006 to obtain interference expression vectors. The powdery mildew-susceptible triticum asetivum l. variety Yangmai 158 is transformed. The identification result of powdery mildew resistance of positive transformed plants shows that the resistance of powdery mildew-susceptible triticum asetivum l. varieties on powdery mildew is improved with decreasing expression of the TaHBP1.

Disclosed herein are methods for forecasting response to lupus nephritis (LN) therapy in individual diagnosed with childhood-onset SLE (cSLE). The methods may include the step of detecting each protein in a protein set in a sample obtained from an individual in need thereof. The protein set may include ceruloplasmin, kidney injury molecule 1 (KIM-1), monocyte chemotactic protein 1 (MCP-1), adiponectin, hemopexin, and NGAL.

The invention discloses a method for producing a heme-binding protein, which is characterized by comprising the following steps: transferring an expression vector containing a heme-binding protein gene expression cassette into a soybean genome and expressing to obtain soybean seeds rich in heme-binding protein, and separating and extracting to obtain the heme-binding protein. The invention provides a method for producing hemoglobin / myoglobin by using transgenic soybean seeds. The hemoglobin / myoglobin produced by the method can be used as a coloring additive and a flavor regulator of food; the invention discloses a promoter and a regulatory sequence which can be highly expressed in soybean seeds. The content of hemoglobin / myoglobin in the soybean seeds of a high-expression strain reaches 0.1% or above of the weight of the seeds; according to the hemoglobin / myoglobin produced from the transgenic soybeans, the production cost is reduced, energy is saved compared with a traditional microbial fermentation method, and the method is a more environment-friendly production mode.

This invention discloses a method for cloning C-terminal fragment of human matrix metalloproteinase 2 from placenta tissues. The recombinant adenovirus is constructed by: extracting total RNA from fresh placenta, performing reverse transcription to obtain the first cDNA strand of hemopexin (PEX) domain, amplifying the cDNA strand with primers (PEX446S and PEX660A) to obtain PEX215 fragment (676bp), amplifying the cDNA strand with primers (PEX462S and PEX660A) to obtain PEX198 fragment (629bp), and ligating fragments PEX215 and PEX198 with GST fusion protein vector pGEX-4T-3 and pGEX-5X-1 respectively to obtain recombinant plasmid pGEX-4T-3 / PEX215 and pGEX-5X-1 / PEX198.

A method for determining at least one protein in the blood which is more precise while still being simple to implement. The method exploits in an original way the spectroscopy and the dosing techniques to determine accurately the content in proteins of the biological sample, notably for oxyhemoglobin, methemoglobin, heme bound to serum albumin and hemopexin and bilirubin. Such method can advantageously be used in various applications concerning heme-related or hemoprotein-related disorders, notably method for diagnosing, for following a treatment, for determining biomarkers or for screening. Such a method is also interesting for qualifying blood bags.

Small molecule inhibitors are claimed that selectively target the hemopexin domain of matrix metalloproteinase 9 (MMP-9) and do not inhibit the protease's catalytic functions. A method of treating cancer in a patient in need thereof with the compounds of the invention is also claimed.

Provided are in vitro serologic methods of assessing the presence of, and assessing the progression of, liver fibrosis in a subject. Also provided are methods of assessing efficacy of an agent for the treatment of liver fibrosis, and methods of treating liver fibrosis. The methods involve quantitatively measuring di-sialylated and mono-sialylated O-glycoforms of a peptide fragment of hemopexin (HPX) in a test serum sample obtained from a test subject, and comparing the measured amounts of di-sialylated and mono-sialylated O-glycoforms of the peptide fragment of hemopexin to a reference amount. In certain embodiments, the measuring is performed using LC-MS / MS-MRM (liquid chromatography / tandem mass spectrometry / multiple reaction monitoring). In certain embodiments, the measuring is performed using LC / MS3 (liquid chromatography with triple-stage mass spectrometric detection).

This invention relates to a method for constructing eukaryotic expression plasmid capable of excreting human hemopexin, and its application. The method comprises: designing two PCR primers PEX446sense and PEX660antisense according to human MMP2 sequence, its coding frame, and multi-coloning sites of pSecTag A vector, amplifying human MMP2 C-terminal segment PEX cDNA by using pGEX-4T-3 / PEX215 plasmid as the template, and constructing prokaryotic expression plasmid pSecTag A / PEX. The method is simple, and prokaryotic expression vector condtructed by using human PEX cDNA as the inserting segment is advantageous for research on human PEX cell function and application. The constructed plasmid can be used as a genetic therapy drug for treating tumors.

A compound of Formula I:wherein:Y is —C(O)NHR1 or —NHC(O)R1;R1 is aryl; is optionally substituted with one or more substituents selected from the group consisting of oxo, F, Cl, Br, I, alkyl, NH2, NHR4, NHC(O)R4, NHC(O)OR4, NR5R6, OH, OR4, SR4, cycloalkyl and aryl; or is optionally substituted with one or more substituents selected from the group consisting of F, Cl, Br, I, CN, NO2, alkyl, C(O)R4, C(O)NHR4, C(O)NR5R6, C(O)OH, C(O)OR4, NH2, NHR4, NHC(O)OR4, NR5R6, OH, OR4, SR4, cycloalkyl and aryl;each R4 is independently alkyl, cycloalkyl, or aryl; each R5 is independently alkyl, cycloalkyl, or aryl; each R6 is independently alkyl, cycloalkyl, or aryl; or each R5 and R6, together with the nitrogen atom to which they are attached, independently form an unsubstituted heterocyclic alkyl or unsubstituted heterocyclic aryl; and X is —S— or —O—; and n is 2, 3, or 4.

The invention belongs to the field of genetic engineering and medicines, and particularly relates to a method for performing Hemopexin protein specific induction and maintaining selective polarization of microglial cells, and applications thereof in treatment of spinal cord injury repair. According to the main technical scheme, the method comprises the following steps: (I) transplanting microglial cells into Hemopexin-knockout mice spinal cord to hinder the microglial cells to be selectively polarized; and (II) co-incubating the Hemopexin protein and microglial cells to be capable of inducing and maintaining the selective polarization of the microglial cells. The Hemopexin-induced microglial cells show an M2 phenotype, so that the repair of the spinal cord nerve injury can be effectively promoted.

The present invention provides a method for modulating (e.g. decreasing) the alkaloid content of a plant (e.g. a tobacco plant), the method comprising modifying said plant by modulating the activity or expression of at least one gene encoding a SOUL haem-binding protein. The present invention also provides for the use of at least one gene encoding a SOUL haem-binding protein for modulating the alkaloid content of a plant, as well as tobacco cells, plants, plant propagation materials, harvested leaves, processed tobaccos, or tobacco products obtainable in accordance with the invention.

The inventors have proposed a novel panel of human plasma protein biomarkers for diagnosing hepatic fibrosis and cirrhosis. Presently there is no reliable non-invasive way of assessing liver fibrosis. A 2D-PAGE based proteomics study was used to identify potential fibrosis biomarkers. Plasma from patients with hepatic cirrhosis induced by infection with the hepatitis C virus (HCV) were analyzed. Several proteins associated with liver scarring and potentially also related to viral infection were identified. These proteins include 14-3-3 protein zeta / delta, adiponectin, afamin, alpha-1-antitrypsin, alpha-2-HS-glycoprotein, apolipoprotein C-III, apolipoprotein E, C4b-binding protein beta chain, intact / cleaved complement C3dg, corticosteroid-binding globulin, fibrinogen gamma chain, beta haptoglobin at pH 5.46-5.49, haptoglobin-related protein, hemopexin, immunoglobulin J chain, leucine-rich alpha-2-glycoprotein, lipid transfer inhibitor protein, retinol-binding protein 4, serum paraoxonase / arylesterase 1, sex hormone-binding globulin and zinc-alpha-2-glycoprotein. These biomarkers can be used in conjunction with polypeptides in WO / 2008 / 031051. The concentrations of these novel biomarkers can be determined using an immunoassay where the concentrations would reflect the extent of fibrosis. A fibrosis scoring scale for each of the novel biomarkers is proposed. The additive result from the scores of all the novel biomarkers would give a more reliable indication of the degree of fibrosis rather than examining individual biomarkers.